Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of JP-1366 (Zastaprazan) in Healthy Volunteers
NCT05712681Phase 1Completed
- Sponsor
- Onconic Therapeutics Inc.
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zastaprazan in gastroesophageal reflux disease (GERD) and gastric ulcer (2 arms), sponsored by Onconic Therapeutics Inc. Primary endpoints: Maximum Plasma Concentration up to 34 hours and Area Under the Curve to the Last Measurable Concentration up to 34 hours. Started Mar 2023; status: completed.
02
Drugs
zastaprazan
03
Conditions
gastroesophageal reflux disease (GERD)gastric ulcer
Beyond the preview
Go deeper on NCT05712681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712681.